|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||August 01, 2019|
|Effective date (End):||July 31, 2020|
|Field of knowledge:||Health Sciences - Medicine - Medical Radiology|
|Principal Investigator:||Marcelo Tatit Sapienza|
|Grantee:||Matheus Zanelatto Junqueira|
|Home Institution:||Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
Prostate cancer is the most common malignant neoplasm in men, excluding non-melanoma skin tumors, accounting for approximately 25% of the new cancers diagnosed in the Brazilian male population. Radioligand therapies have shown promise in the treatment of specific neoplasms. Lutetium-177 labeled PSMA (177Lu-PSMA-617) has been used for patients with metastatic carcinoma resistant to chemical castration (mCPMRC). However ionizing radiation can induce lesions in the salivary glands, causing discomfort and complaints such as "dry mouth" and halitosis, which can occur frequently when the dose of radiation exceeds the limits of 40Gy. In the treatment with 177Lu-PSMA, the salivary gland is the organ with the highest radiation absorbed dose (approximately 1.0 Gy / GBq). Specific measures may be employed in an attempt to reduce the dose of radiation absorbed by the salivary glands, in order to reduce the side effects. Cervical cutaneous cooling is one of the measures proposed empirically to reduce the uptake in salivary glands. This project aims to determine the effect of salivary gland cooling on the reduction of 68Ga-PSMA radiopharmaceutical uptake, which has an uptake mechanism similar to 177Lu-PSMA, in order to predict the efficacy of the maneuver in decreasing the radiation dose in the salivary glands in a therapeutic context.